Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422799 · ClinicalTrials.gov registry record · Phase 2
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00422799 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 63 participants.
The verdict
NCT00422799, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
In this study, we are trying to find out if the combination of these two drugs is effective in treating Waldenstrom's macroglobulinemia (WM). The combination of these two drugs has not been studied for patients with relapsed or refractory macroglobulinemia. The U.S. Food and Drug Administration (FDA) has approved bortezomib for the treatment of multiple myeloma, a cancer that is closely related to Waldenstrom's macroglobulinemia.
Interventions
- DRUG Rituximab
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-08-30 |
| Est. Completion | 2015-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422799
The ClinicalTrials.gov registry entry for NCT00422799 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00422799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422799 about?
NCT00422799 is a clinical study titled "Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)". In this study, we are trying to find out if the combination of these two drugs is effective in treating Waldenstrom's macroglobulinemia (WM). The combination of these two drugs has not been studied for patients with relapsed or refractory macroglobulinemia. The U.S. Food and Drug Administration (FDA...
What is the current status of trial NCT00422799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2006-08-30. Estimated completion is 2015-10-09.
What interventions are being tested in trial NCT00422799?
The interventions under investigation include: Rituximab (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00422799?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.